We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+33.87%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$336M
AUM Growth
+$6.15M
Cap. Flow
-$58M
Cap. Flow %
-17.27%
Top 10 Hldgs %
38.74%
Holding
96
New
16
Increased
28
Reduced
16
Closed
29

Top Buys

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$11.9M
2
SNY icon
Sanofi
SNY
+$10.8M
3
MDT icon
Medtronic
MDT
+$10.3M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$8.45M
5
CLDX icon
Celldex Therapeutics
CLDX
+$7.27M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$20.7M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.2M
3
SLNO
Soleno Therapeutics
SLNO
+$8.43M
4
KRYS icon
Krystal Biotech
KRYS
+$8.3M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.41M

Sector Composition

Rank Sector Weight
1 Healthcare 96.5%
2 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TELA icon
26
TELA Bio
TELA
$30.3M
$5.26M 1.57%
795,080
+304,609
+62% +$1.76M
BIIB icon
27
Biogen
BIIB
$30.9B
$5.18M 1.54%
20,000
-8,069
-29% -$1.98M
CBAY
28
DELISTED
Cymabay Therapeutics
CBAY
$5.17M 1.54%
218,975
-371,025
-63% -$6.61M
CRBU icon
29
Caribou Biosciences
CRBU
$146M
$5.16M 1.54%
900,818
+8,032
+0.9% +$39.7K
SRRK icon
30
Scholar Rock
SRRK
$5.88B
$5.08M 1.51%
270,000
+260,289
+2,680% +$3.24M
PEN icon
31
Penumbra
PEN
$12.6B
$5.03M 1.5%
+20,000
New +$4.42M
INSM icon
32
Insmed
INSM
$22.4B
$4.82M 1.43%
155,504
+5,117
+3% +$133K
SRPT icon
33
Sarepta Therapeutics
SRPT
$1.64B
$4.52M 1.35%
46,884
+37,687
+410% +$3.62M
DXCM icon
34
DexCom
DXCM
$29B
$3.85M 1.15%
+31,000
New +$3.17M
SLDB icon
35
Solid Biosciences
SLDB
$792M
$3.65M 1.09%
+594,855
New +$1.9M
UTHR icon
36
United Therapeutics
UTHR
$26.1B
$3.6M 1.07%
16,360
-15,064
-48% -$3.47M
TERN
37
DELISTED
Terns Pharmaceuticals
TERN
$3.36M 1%
516,999
+16,999
+3% +$89.9K
CERS icon
38
Cerus
CERS
$575M
$3.24M 0.96%
1,499,851
+295,961
+25% +$488K
KOD icon
39
Kodiak Sciences
KOD
$2.5B
$3.04M 0.9%
1,000,000
-114,461
-10% -$255K
BHVN icon
40
Biohaven
BHVN
$2.02B
$3.03M 0.9%
70,695
+60,695
+607% +$1.89M
MLTX icon
41
MoonLake Immunotherapeutics
MLTX
$1.56B
$3.02M 0.9%
+50,000
New +$2.58M
SLNO
42
DELISTED
Soleno Therapeutics
SLNO
$2.97M 0.88%
73,665
-296,335
-80% -$8.43M
EVGN icon
43
Evogene
EVGN
$5.83M
$2.6M 0.78%
310,000
– –
MIRM icon
44
Mirum Pharmaceuticals
MIRM
$6.56B
$2.39M 0.71%
80,811
-29,303
-27% -$887K
KALV
45
CALL
DELISTED
KalVista Pharmaceuticals
KALV
$2.21M 0.66%
180,400
-350,000
-66% -$3.18M
ZURA icon
46
Zura Bio
ZURA
$504M
$2.16M 0.64%
462,997
+58,957
+15% +$295K
ANNX icon
47
Annexon
ANNX
$796M
$1.9M 0.56%
417,429
+17,713
+4% +$43.8K
CGEN icon
48
Compugen
CGEN
$212M
$1.86M 0.55%
940,000
+589,812
+168% +$515K
ARGX icon
49
argenx
ARGX
$55.2B
$1.84M 0.55%
+4,826
New +$2.25M
ETNB
50
DELISTED
89bio
ETNB
$1.77M 0.53%
158,719
+98,472
+163% +$905K
1
2
3 4

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return
ADIC
Abu Dhabi Investment Council Abu Dhabi, United Arab Emirates $975M AUM

Silverarc Capital Management's Q4 2023 Portfolio in Review

As of Q4 2023, Silverarc Capital Management held 96 positions worth $336M, up 1.9% from $330M the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Silverarc Capital Management withdrew a net $58M in Q4 2023, closing 29 positions and reducing 16 holdings. Its most notable exit was Immunogen Inc, an estimated $20.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 81% a quarter earlier, followed by Consumer Staples.

Against the trend, Silverarc Capital Management opened a new position in Nuvalent worth $14.2M.

  • Silverarc Capital Management's largest Q4 2023 buy was Nuvalent: 193,000 shares worth $14.2M.
  • Silverarc Capital Management added most to Akero Therapeutics in Q4 2023, an estimated $4.3M increase.
  • Silverarc Capital Management's biggest Q4 2023 reduction was Soleno Therapeutics, cutting an estimated $8.43M.
  • Silverarc Capital Management fully exited Immunogen Inc in Q4 2023, selling an estimated $20.7M.
  • Silverarc Capital Management's ten largest holdings make up 39% of its $336M portfolio in Q4 2023.
  • Silverarc Capital Management opened 16 new positions and closed 29 in Q4 2023.
  • Silverarc Capital Management's portfolio value rose 1.9% quarter-over-quarter to $336M.

Based on Silverarc Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.